Overview

HIV PrEP Priming of Immune Effectors

Status:
Unknown status
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
Can HIV-specific immunity develop in HIV uninfected humans exposed to HIV whilst receiving antiretroviral pre-exposure prophylaxis (PrEP)? Investigators will investigate this possibility in commercial sex workers in Kampala who will be receiving Truvada PrEP for one year.
Phase:
Phase 4
Details
Lead Sponsor:
MRC/UVRI and LSHTM Uganda Research Unit
MRC/UVRI Uganda Research Unit on Aids
Treatments:
Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
Tenofovir